NO823672L - Immunkompleks-fjerning og utvikling av tumorspesifikt antilegeme ved immobilisert protein a perfusjon og postperfusjon-legemiddelinfusjon - Google Patents

Immunkompleks-fjerning og utvikling av tumorspesifikt antilegeme ved immobilisert protein a perfusjon og postperfusjon-legemiddelinfusjon

Info

Publication number: NO823672L
Authority: NO; Norway
Prior art keywords: plasma; immobilized; perfusion; protein; spa
Prior art date: 1981-11-06

Application number

NO823672A

Other languages

English (en)

Norwegian (no)

Inventor

David Stephen Terman

Original Assignee

Baylor College Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-11-06

Filing date

1982-11-04

Publication date

1983-05-09

1982-11-04 Application filed by Baylor College Medicine filed Critical Baylor College Medicine

1983-05-09 Publication of NO823672L publication Critical patent/NO823672L/no

Links

206010028980 Neoplasm Diseases 0.000 title claims description 90
102000004169 proteins and genes Human genes 0.000 title claims description 85
108090000623 proteins and genes Proteins 0.000 title claims description 85
230000010412 perfusion Effects 0.000 title claims description 71
238000001802 infusion Methods 0.000 title description 15
238000011161 development Methods 0.000 title description 8
108010058683 Immobilized Proteins Proteins 0.000 claims description 62
239000002245 particle Substances 0.000 claims description 59
238000000034 method Methods 0.000 claims description 47
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 43
210000004369 blood Anatomy 0.000 claims description 31
239000008280 blood Substances 0.000 claims description 31
210000004027 cell Anatomy 0.000 claims description 31
230000001225 therapeutic effect Effects 0.000 claims description 26
201000011510 cancer Diseases 0.000 claims description 22
239000012528 membrane Substances 0.000 claims description 18
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 13
239000007787 solid Substances 0.000 claims description 12
238000012360 testing method Methods 0.000 claims description 11
210000004881 tumor cell Anatomy 0.000 claims description 11
229940079593 drug Drugs 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 10
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
230000002285 radioactive effect Effects 0.000 claims description 8
239000007788 liquid Substances 0.000 claims description 6
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 5
230000037396 body weight Effects 0.000 claims description 5
230000000694 effects Effects 0.000 claims description 5
239000012530 fluid Substances 0.000 claims description 5
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 4
229940009456 adriamycin Drugs 0.000 claims description 4
229960004397 cyclophosphamide Drugs 0.000 claims description 4
-1 plasma Substances 0.000 claims description 4
238000005406 washing Methods 0.000 claims description 4
230000015572 biosynthetic process Effects 0.000 claims description 3
231100000252 nontoxic Toxicity 0.000 claims description 3
230000003000 nontoxic effect Effects 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
208000007536 Thrombosis Diseases 0.000 claims description 2
230000000541 pulsatile effect Effects 0.000 claims description 2
STUSTWKEFDQFFZ-UHFFFAOYSA-N Chlordimeform Chemical compound CN(C)C=NC1=CC=C(Cl)C=C1C STUSTWKEFDQFFZ-UHFFFAOYSA-N 0.000 claims 7
239000003550 marker Substances 0.000 claims 5
238000002347 injection Methods 0.000 claims 3
239000007924 injection Substances 0.000 claims 3
210000002381 plasma Anatomy 0.000 description 94
238000011282 treatment Methods 0.000 description 81
239000003610 charcoal Substances 0.000 description 53
210000002966 serum Anatomy 0.000 description 27
241000282472 Canis lupus familiaris Species 0.000 description 21
230000004044 response Effects 0.000 description 20
239000002953 phosphate buffered saline Substances 0.000 description 16
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
210000000779 thoracic wall Anatomy 0.000 description 14
230000002476 tumorcidal effect Effects 0.000 description 14
210000004379 membrane Anatomy 0.000 description 12
206010006187 Breast cancer Diseases 0.000 description 11
230000036772 blood pressure Effects 0.000 description 11
201000008274 breast adenocarcinoma Diseases 0.000 description 10
230000000747 cardiac effect Effects 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
230000004087 circulation Effects 0.000 description 9
230000009467 reduction Effects 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
230000006378 damage Effects 0.000 description 8
210000001165 lymph node Anatomy 0.000 description 8
231100000419 toxicity Toxicity 0.000 description 8
230000001988 toxicity Effects 0.000 description 8
208000002193 Pain Diseases 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
238000011156 evaluation Methods 0.000 description 7
238000009169 immunotherapy Methods 0.000 description 7
230000003902 lesion Effects 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
210000003462 vein Anatomy 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
230000004872 arterial blood pressure Effects 0.000 description 6
230000017531 blood circulation Effects 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
238000011835 investigation Methods 0.000 description 6
210000004180 plasmocyte Anatomy 0.000 description 6
230000002269 spontaneous effect Effects 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
230000005909 tumor killing Effects 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
108020004414 DNA Proteins 0.000 description 5
102000053602 DNA Human genes 0.000 description 5
241000282414 Homo sapiens Species 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
208000027418 Wounds and injury Diseases 0.000 description 5
229940098773 bovine serum albumin Drugs 0.000 description 5
210000000481 breast Anatomy 0.000 description 5
229940027941 immunoglobulin g Drugs 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
208000014674 injury Diseases 0.000 description 5
230000001394 metastastic effect Effects 0.000 description 5
206010061289 metastatic neoplasm Diseases 0.000 description 5
238000003127 radioimmunoassay Methods 0.000 description 5
206010072960 Chest wall tumour Diseases 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
208000025865 Ulcer Diseases 0.000 description 4
230000034994 death Effects 0.000 description 4
238000001914 filtration Methods 0.000 description 4
210000002758 humerus Anatomy 0.000 description 4
238000005259 measurement Methods 0.000 description 4
208000018223 neoplasm of chest wall Diseases 0.000 description 4
230000036581 peripheral resistance Effects 0.000 description 4
239000002504 physiological saline solution Substances 0.000 description 4
230000001698 pyrogenic effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000001179 sorption measurement Methods 0.000 description 4
239000008223 sterile water Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
208000026310 Breast neoplasm Diseases 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 3
206010030113 Oedema Diseases 0.000 description 3
208000024434 abnormal chest sound Diseases 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000002146 bilateral effect Effects 0.000 description 3
210000003109 clavicle Anatomy 0.000 description 3
230000000004 hemodynamic effect Effects 0.000 description 3
230000003100 immobilizing effect Effects 0.000 description 3
239000010410 layer Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
230000002956 necrotizing effect Effects 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
210000001147 pulmonary artery Anatomy 0.000 description 3
239000000376 reactant Substances 0.000 description 3
239000000523 sample Substances 0.000 description 3
238000000926 separation method Methods 0.000 description 3
229910001220 stainless steel Inorganic materials 0.000 description 3
239000010935 stainless steel Substances 0.000 description 3
230000019432 tissue death Effects 0.000 description 3
230000036269 ulceration Effects 0.000 description 3
101710164309 56 kDa type-specific antigen Proteins 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
208000019693 Lung disease Diseases 0.000 description 2
206010027458 Metastases to lung Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000191967 Staphylococcus aureus Species 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
230000036770 blood supply Effects 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
231100000313 clinical toxicology Toxicity 0.000 description 2
239000000084 colloidal system Substances 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
230000035876 healing Effects 0.000 description 2
238000010324 immunological assay Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000011068 loading method Methods 0.000 description 2
210000005075 mammary gland Anatomy 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
230000004660 morphological change Effects 0.000 description 2
GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 2
229960000515 nafcillin Drugs 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
210000004224 pleura Anatomy 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
239000000700 radioactive tracer Substances 0.000 description 2
239000002356 single layer Substances 0.000 description 2
239000002002 slurry Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
241000894007 species Species 0.000 description 2
238000001709 templated self-assembly Methods 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
101100204059 Caenorhabditis elegans trap-2 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
206010010075 Coma hepatic Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
210000000712 G cell Anatomy 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000024781 Immune Complex disease Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010027457 Metastases to liver Diseases 0.000 description 1
206010027463 Metastases to pleura Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
241001077673 Mylon Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
108091093105 Nuclear DNA Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
208000002151 Pleural effusion Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
206010067868 Skin mass Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
206010051017 Staphylococcal bacteraemia Diseases 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
210000004712 air sac Anatomy 0.000 description 1
208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003172 anti-dna Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
244000309466 calf Species 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000007681 cardiovascular toxicity Effects 0.000 description 1
231100000060 cardiovascular toxicity Toxicity 0.000 description 1
230000030833 cell death Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
230000000349 chemoimmunotherapeutic effect Effects 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
238000011976 chest X-ray Methods 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
238000004581 coalescence Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
230000009266 disease activity Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
239000003517 fume Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
201000001059 hepatic coma Diseases 0.000 description 1
208000007386 hepatic encephalopathy Diseases 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
230000003908 liver function Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000002624 low-dose chemotherapy Methods 0.000 description 1
231100000516 lung damage Toxicity 0.000 description 1
210000001349 mammary artery Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
238000009629 microbiological culture Methods 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
231100000381 nephrotoxic Toxicity 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
235000021542 oral nutrition Nutrition 0.000 description 1
239000011368 organic material Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
230000006920 protein precipitation Effects 0.000 description 1
230000035485 pulse pressure Effects 0.000 description 1
239000005297 pyrex Substances 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000007790 scraping Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
231100000004 severe toxicity Toxicity 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011343 solid material Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
230000002885 thrombogenetic effect Effects 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
210000002303 tibia Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
208000025883 type III hypersensitivity disease Diseases 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents

Landscapes

Health & Medical Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
Biodiversity & Conservation Biology (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
External Artificial Organs (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO823672A 1981-11-06 1982-11-04 Immunkompleks-fjerning og utvikling av tumorspesifikt antilegeme ved immobilisert protein a perfusjon og postperfusjon-legemiddelinfusjon NO823672L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US32332681A	1981-11-06	1981-11-06

Publications (1)

Publication Number	Publication Date
NO823672L true NO823672L (no)	1983-05-09

Family

ID=23258717

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO823672A NO823672L (no)	1981-11-06	1982-11-04	Immunkompleks-fjerning og utvikling av tumorspesifikt antilegeme ved immobilisert protein a perfusjon og postperfusjon-legemiddelinfusjon

Country Status (10)

Country	Link
EP (1)	EP0079221A3 (fr)
JP (1)	JPS5886168A (fr)
KR (1)	KR840002244A (fr)
AU (1)	AU570911B2 (fr)
CA (1)	CA1197460A (fr)
DK (1)	DK487382A (fr)
ES (3)	ES517174A0 (fr)
FI (1)	FI823761L (fr)
IL (1)	IL66959A0 (fr)
NO (1)	NO823672L (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60120821A (ja) *	1983-12-05	1985-06-28	Asahi Chem Ind Co Ltd	悪性腫瘍治療用白血球刺激材および刺激方法
DE3422435A1 (de) *	1984-06-16	1986-01-16	B. Braun Melsungen Ag, 3508 Melsungen	Verfahren und vorrichtung zur selektiven abtrennung pathologischer und/oder toxischer spezies aus blut oder blutplasma unter verwendung von filterkerzen
US4704366A (en) *	1984-06-22	1987-11-03	Bio-Rad Laboratories, Inc.	Process for binding IgG to protein A
US4614513A (en) *	1984-08-13	1986-09-30	Fred Hutchinson Cancer Research Center	Method and apparatus for treatment to remove immunoreactive substances from blood
US5122112A (en) *	1986-11-21	1992-06-16	Imre Corporation	Antigen-specific removal of circulating immune complexes
SE8801426D0 (sv) *	1988-04-15	1988-04-15	Ulf Rothman	Forfarande och medel for blodbehandling

1982
- 1982-10-07 AU AU89189/82A patent/AU570911B2/en not_active Ceased
- 1982-10-11 IL IL66959A patent/IL66959A0/xx unknown
- 1982-11-03 DK DK487382A patent/DK487382A/da not_active Application Discontinuation
- 1982-11-03 FI FI823761A patent/FI823761L/fi not_active Application Discontinuation
- 1982-11-04 NO NO823672A patent/NO823672L/no unknown
- 1982-11-05 CA CA000415005A patent/CA1197460A/fr not_active Expired
- 1982-11-05 EP EP82305913A patent/EP0079221A3/fr not_active Withdrawn
- 1982-11-05 ES ES517174A patent/ES517174A0/es active Granted
- 1982-11-06 JP JP57195196A patent/JPS5886168A/ja active Pending
- 1982-11-06 KR KR1019820005015A patent/KR840002244A/ko unknown
1983
- 1983-07-01 ES ES523791A patent/ES523791A0/es active Granted
- 1983-07-01 ES ES523790A patent/ES8501984A1/es not_active Expired

Also Published As

Publication number	Publication date
FI823761A0 (fi)	1982-11-03
ES523790A0 (es)	1984-12-16
AU8918982A (en)	1985-02-07
ES8402506A1 (es)	1983-12-01
ES517174A0 (es)	1983-12-01
FI823761L (fi)	1983-05-07
CA1197460A (fr)	1985-12-03
AU570911B2 (en)	1988-03-31
JPS5886168A (ja)	1983-05-23
EP0079221A2 (fr)	1983-05-18
EP0079221A3 (fr)	1986-01-22
ES8503202A1 (es)	1984-12-16
IL66959A0 (en)	1983-02-23
DK487382A (da)	1983-05-07
ES8501984A1 (es)	1984-12-16
ES523791A0 (es)	1984-12-16
KR840002244A (ko)	1984-06-25

Publication	Publication Date	Title
US5091091A (en)	1992-02-25	Protein A perfusion and post perfusion drug infusion
Pollak et al.	1956	Renal vein thrombosis and the nephrotic syndrome
Greaves et al.	1969	Immunosuppressive potency and in-vitro activity of antilymphocyte globulin
Smart et al.	2018	Large-volume crystalloid fluid is associated with increased hyaluronan shedding and inflammation in a canine hemorrhagic shock model
Smith	1999	Neutrophil activation and mediators of inflammation in chronic venous insufficiency
Cooper et al.	2000	Hypothermic circulatory arrest causes multisystem vascular endothelial dysfunction and apoptosis
JPH09501066A (ja)	1997-02-04	全血またはその成分からの選択された因子の除去
Stableforth et al.	1976	Acquired von Willebrand syndrome with inhibitors both to factor VIII clotting activity and ristocetin‐induced platelet aggregation
Terman et al.	1977	Specific removal of antibody by extracorporeal circulation over antigen immobilized in collodion-charcoal.
Kellum et al.	2003	Blood purification in non-renal critical illness
Smith et al.	2015	The early diagnosis of acute and latent plumbism
Staubach et al.	2003	A new endotoxin adsorption device in Gram-negative sepsis: use of immobilized albumin with the MATISSE® adsorber
Christensen	1970	A reversible vascular abnormality associated with diabetic ketosis
NO823672L (no)	1983-05-09	Immunkompleks-fjerning og utvikling av tumorspesifikt antilegeme ved immobilisert protein a perfusjon og postperfusjon-legemiddelinfusjon
Parving et al.	1974	Increased transcapillary escape rate of albumin, IgG, and IgM during angiotensin-II-induced hypertension in man
RAYNER et al.	1960	Intestinal tissue blood flow in shock due to endotoxin
Fischer et al.	2015	Arterial stiffness and renal replacement therapy: a controversial topic
Dieter et al.	1949	Studies on an undetermined circulating anticoagulant. Case report and laboratory findings
Burns-Cox et al.	1972	Risk factors and the absence of coronary heart disease in aborigines in West Malaysia.
NZ202367A (en)	1987-08-31	Therapeutic immunoadsorbent based on non-covalently immobilised protein a; blood plasma perfusion method and perfusion system
Sargent et al.	1970	Studies of cryoprecipitation: III. Hemodynamic and metabolic adaptation to a circulating single component cryoglobulin
Dagli et al.	2016	Relation of neutrophil/lymphocyte ratio to resistant hypertension
Sideman et al.	1977	Removal of bilirubin from the blood of jaundiced infants
SAHIN	2018	Relationships between the Microvascular Complications of Diabetes Mellitus (DM) and Natural Coagulation Inhibitors and Anticardiolipin (ACA) Antibodies
Kawana et al.	1986	Value of the assay for IgA-containing circulating immune complexes in Henoch-Schönlein purpura